Rocket Pharmaceuticals, Inc. Available-for-sale Securities
Rocket Pharmaceuticals, Inc. (RCKT) had Available-for-sale Securities of $11.56 million as of 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2018-05-11
- 2018-03-31: Available-for-sale Securities $11.56M.
- 2017-12-31: Available-for-sale Securities $21.29M.
- 2017-09-30: Available-for-sale Securities $53.98M.
- 2017-06-30: Available-for-sale Securities $81.14M.
| Period end | Available-for-sale Securities |
|---|---|
| 2018-03-31 | $11.56M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $21.29M 10-K · filed 2018-03-07 |
| 2017-09-30 | $53.98M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $81.14M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $89.43M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $96.67M 10-K · filed 2018-03-07 |
| 2016-09-30 | $54.58M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $59.70M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $43.56M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $31.24M 10-K · filed 2017-03-16 |
| 2015-09-30 | $29.12M 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |